Acolyte and Ploughshare Innovations Agree Exclusive Licence For Adenylate Kinase
AK technology was originally developed by the Defence Science and Technology Laboratory an agency of UK Ministry of Defence. Ploughshare Innovations have responsibility for managing the commercial exploitation of the technology under the AK Rapid® brand.
Unlike ATP, AK is present at constant levels in all eukaryotic and prokaryotic cells irrespective of the organism's metabolic state. The amplification of the conversion of ADP to ATP gives sensitivities up to 100 times those of standard ATP bioluminescence and up to 1 million times those of conventional optical measurements.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.